Research Translation for All Persons: A Discussion of the ADRC Network Role

October 21, 2022

Fall 2022 ADRC Meeting
Chicago, Illinois

Amy Kind, MD, PhD
University of Wisconsin School of Medicine and Public Health
FUNDING DISCLOSURES

NIH/National Institute on Aging

NIH/National Institute on Minority Health and Health Disparities

Alzheimer's Association

Amy Kind, MD, PhD
amy.kind@wisc.edu
BRAIN HEALTH IS NOT DISTRIBUTED EQUALLY

Solutions Needed
1. Improving representation in clinical research is **urgent**.

2. Improving representation in clinical research **requires investment**.

3. Improving representation **requires transparency and accountability**.

4. Improving representation in clinical research is the **responsibility of everyone** involved in the clinical research enterprise.

5. Creating a more equitable future entails a **paradigm shift**.

**NASEM Report, “Improving Representation in Clinical Trials and Research,” 2022**
“The US is experiencing a decline in life expectancy …. As part of a wider effort to reverse this decline, relationships between FDA and the biomedical ecosystem should be reimagined to facilitate more effective translation of science into successful health interventions... the biomedical community should review its priorities so that it can deliver more new therapies… particularly for those suffering most: racial and ethnic minorities, people with less education and wealth, and those living in rural areas.”

-- Robert M. Califf, FDA Commissioner (Califf, Science, 2022)
RESPONSIBILITY

ADRC Role....

“The Alzheimer’s Disease Research Centers (ADRC) network is funded by the National Institute on Aging (NIA) to find treatments and prevention strategies for Alzheimer’s Disease (AD) and other related dementias, as well as to translate research findings into improved diagnosis and care”… for all persons.

*https://www.nia.nih.gov/research/adc
NIH HEALTH DISPARITIES PRIORITY POPULATIONS

• Hispanics/Latinos
• American Indians/Alaskan Natives
• Blacks/African Americans
• Asian Americans
• Native Hawaiians and Other Pacific Islanders
• Socioeconomically Disadvantaged Populations
• Rural Populations
• Disability Populations
• Sexual and Gender Minorities
• Others

**Hill, Perez-Stable, Anderson and Bernard, Ethnicity and Disease, 2015; https://www.nia.nih.gov/research/osp/framework**
INTERVENTIONS

Treatments

Clinical and Social Interventions
INTERVENTIONS FOR ALL— BARRIERS ARE MANY

Treatments
Improving Representation in Clinical Trials and Research

Building Research Equity for Women and Underrepresented Groups
“Investments are needed in the systems and technologies that **reduce burdens to participation** by underrepresented and excluded populations, **such as** by **adequately compensating** participants financially for their time when participating in research and by investing resources in making participation more **physically accessible**, and by providing **research materials** that are culturally informed and multilingual.”

**NASEM Report, “Improving Representation in Clinical Trials and Research,” 2022**
INTERVENTIONS FOR ALL REQUIRE SUPPORTS

Treatments
ONE MAJOR BARRIER

$
INTERVENTIONS

Treatments

Clinical and Social Interventions

Policy
POWER OF POLICY
AREA DEPRIVATION INDEX (ADI)* - AN EXPOZONE METRIC

- ADI construction
  - 17 measures of social determinants of health across small, population sensitive areas
  - Ranked score

- Current ADI measures for full US available through the Neighborhood Atlas®*

- Similar metrics available in most countries

- ADI in UDS 4.0; launching ADI in ACTC, ADNI and many others

*Kind and Buckingham, New England Journal of Medicine, 2018
ADI IS NOW LEVERAGED IN US HEALTH POLICY

Ethical Allocation of COVID Therapies

• Example: Pennsylvania

US Centers for Medicare and Medicaid Services (CMS)

• 2023 ACO Realizing Equity, Access, and Community Health (REACH) Model uses ADI to adjust payments

CENTER FOR MEDICARE AND MEDICAID INNOVATION (CMMI)

A health system that achieves equitable outcomes through high quality, affordable, person-centered care.

- Drive Accountable Care
- Advance Health Equity
- Support Innovation
- Address Affordability
- Partner to Achieve System Transformation
## Health Equity Benchmark Adjustment

ACO REACH includes a benchmark adjustment that increases benchmarks for ACOs serving higher proportions of underserved beneficiaries.

CMS will stratify all beneficiaries aligned to ACO REACH using a composite measure of underservice that incorporates a combination of:

<table>
<thead>
<tr>
<th>Percentile Range</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>91st – 100th Percentile</td>
<td>+$30 PBPM</td>
</tr>
<tr>
<td>51st – 90th Percentile</td>
<td>No Adjustment</td>
</tr>
<tr>
<td>1st – 50th Percentile</td>
<td>-$6 PBPM Adjustment</td>
</tr>
</tbody>
</table>

1. CMS may explore other variables to include in this assessment and will notify applicants prior to the start of PY2023 if any other variables are included.

*2022 ACO Realizing Equity, Access, and Community Health (REACH) Model [https://innovation.cms.gov/media/document/aco-reach-fin-meth-webinar-slides]*
CMS EQUITY APPROACH: PROVIDES FUNDING TO REMOVE BARRIERS TO TREATMENT
CMS ACO-REACH RESOURCE TARGETING: SIMPLIFIED

Low ADI = $  
High ADI = $
QUESTIONS FOR DISCUSSION

• Should ADRC Network launch efforts towards creating an equity-focused policy standard for interventional trials in alignment with the National Academies report?

• Should financing of interventional research trials be grounded to principles of equity in alignment with CMS payment policy?

• What is the role of the ADRC network in setting equity-aligned standards for industry and other intervention studies?
The NACC database is funded by NIA/NIH Grant U24 AG072122. Data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wissniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovi, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD).